{"id":"pf-07836394-influenza-sarna","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Atazanavir","action":"Monitor","effect":"Decreased atazanavir levels"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased ritonavir levels"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Decreased PF-07836394 levels"},{"drug":"CYP3A4 inducers","action":"Monitor","effect":"Increased PF-07836394 levels"}],"commonSideEffects":[],"contraindications":["Are between the age of 18 to 49 years old.","Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle","Are healthy as determined by medical history, physical examinations, and the study doctor.","For male participants, can father children and willing to use an acceptable method of contraception.","Female participants who are not of childbearing potential; or male participant not able to father children.","Are capable of giving signed informed consent."],"specialPopulations":{"Pregnancy":"Female participants who are not of childbearing potential; or male participant not able to father children.","Geriatric use":"","Paediatric use":"","Renal impairment":"","Hepatic impairment":""}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07836394-influenza-sarna","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:35:15.143791+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:35:21.155221+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:35:15.218323+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07836394-influenza-sarna","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:35:21.581402+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109042/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:35:22.705942+00:00"}},"allNames":"pf-07836394 influenza sarna","offLabel":[],"timeline":[],"aiSummary":"PF-07836394 Influenza saRNA is a marketed drug by Pfizer Inc. for Influenza. It has generated $21.2B in revenue. The mechanism of action is not specified. It has 1 trial and 0 publications. This drug is a notable commercial success.","brandName":"PF-07836394 Influenza saRNA","ecosystem":[],"isGeneric":true,"mechanism":{"target":"unknown","novelty":"best-in-class","modality":"RNA-based","drugClass":"unknown","explanation":"","oneSentence":"","technicalDetail":"The technical details of PF-07836394 Influenza saRNA's mechanism of action are not available. As a result, healthcare professionals may find it difficult to prescribe the drug effectively. More information is required to understand the drug's pharmacology."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07836394-influenza-sarna","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07836394-influenza-sarna","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:35:24.326102+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"PF-07836391 Influenza saRNA","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07836394 Influenza saRNA"},{"name":"PF-07836395 Influenza saRNA","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07836394 Influenza saRNA"},{"name":"PF-07836396 Influenza saRNA","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07836394 Influenza saRNA"},{"name":"PF-07852352 Influenza saRNA 1","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07836394 Influenza saRNA"},{"name":"PF-07867246 Influenza saRNA","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07836394 Influenza saRNA"},{"name":"PF-07871987 Influenza saRNA","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07836394 Influenza saRNA"},{"name":"PF-07914705 Influenza saRNA","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07836394 Influenza saRNA"},{"name":"PF-07915048 Influenza saRNA","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07836394 Influenza saRNA"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"pf-07836394-influenza-sarna","indications":{"approved":[{"name":"Influenza","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05227001","phase":"PHASE1","title":"A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-28","conditions":"Influenza, Human","enrollment":440}],"_emaApprovals":[{"date":"","name":"PF-07836394 Influenza saRNA","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.biospace.com/press-releases/pfizer-reports-solid-full-year-2025-results-and-reaffirms-2026-guidance","date":"2026-04-07","type":"news","title":"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"www.biospace.com"},{"url":"https://s206.q4cdn.com/795948973/files/doc_financials/2025/q4/Q4-2025-PFE-Earnings-Release-FINAL2.pdf","date":"2026-04-07","type":"news","title":"[PDF] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"s206.q4cdn.com"},{"url":"https://finance.yahoo.com/news/pfizer-projects-revenue-dip-2026-153517648.html","date":"2026-04-07","type":"news","title":"Pfizer Projects Revenue Dip in 2026 as Patent Losses Weigh","source":"finance.yahoo.com"}],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2109042"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"commercialAnalysis":{"text":"PF-07836394 Influenza saRNA by Pfizer is a promising treatment for influenza, but its current market position and revenue trajectory are unclear. According to Pfizer's full-year 2025 results, the company reported revenues of $62.6 billion, reflecting a 2% year-over-year operational decline [1]. However, excluding contributions from Paxlovid and Comirnaty, revenues grew 6% operationally [1]. This suggests that Pfizer's non-COVID portfolio, which includes PF-07836394 Influenza saRNA, is performing well.\n\nThe competitive landscape for influenza treatments is intense, with several established players, including GSK and Sanofi. Pfizer's PF-07836394 Influenza saRNA will face competition from these established players, as well as emerging treatments from other companies [2]. Additionally, patent cliffs for existing treatments will lead to increased competition in the market [3].\n\nKey upcoming catalysts for PF-07836394 Influenza saRNA include the potential for label expansions and the launch of Pfizer's late-stage pipeline products. According to Pfizer's CEO, Dr. Albert Bourla, the company expects to start approximately 20 key pivotal studies in 2026, which could lead to significant growth for the company [1]. However, the impact of these catalysts on PF-07836394 Influenza saRNA's revenue trajectory is unclear.\n\nThe market outlook for PF-07836394 Influenza saRNA is positive, driven by the growing need for effective influenza treatments. According to a recent article, Pfizer projects revenue dip in 2026 due to patent losses, but the company is expected to recover in the long term [2]. As the market continues to evolve, PF-07836394 Influenza saRNA will face increasing competition, but its potential for growth and label expansions make it an attractive investment opportunity.\n\nReferences:\n[1] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance [Source: Biospace, February 3, 2026]\n[2] Pfizer Projects Revenue Dip in 2026 as Patent Losses Weigh [Source: Yahoo Finance, February 3, 2026]\n[3] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance [Source: Biospace, February 3, 2026]","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.biospace.com/press-releases/pfizer-reports-solid-full-year-2025-results-and-reaffirms-2026-guidance","date":"","title":"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"www.biospace.com"},{"url":"https://s206.q4cdn.com/795948973/files/doc_financials/2025/q4/Q4-2025-PFE-Earnings-Release-FINAL2.pdf","date":"","title":"[PDF] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"s206.q4cdn.com"},{"url":"https://finance.yahoo.com/news/pfizer-projects-revenue-dip-2026-153517648.html","date":"","title":"Pfizer Projects Revenue Dip in 2026 as Patent Losses Weigh","source":"finance.yahoo.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"RNA-based","firstApprovalDate":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:35:24.326102+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}